BillionToOne, Inc. (BLLN) vs GRAIL, Inc. (GRAL)
- BillionToOne, Inc. BLLN 98.06 −4.55%
- GRAIL, Inc. GRAL 117.81 −13.03%
BillionToOne, Inc. and GRAIL, Inc. are both Diagnostics & Research companies. GRAIL, Inc. is the larger, with a market value of $6.1B against $4.9B — 1.2× the size. GRAIL, Inc. has negative trailing earnings, so its P/E is not meaningful; BillionToOne, Inc. trades at 95.0×. BillionToOne, Inc. has the higher net margin (8.35% vs −237.0%) and the higher return on invested capital (34.1% vs −20.8%). Across the 16 metrics below, BillionToOne, Inc. leads on 14 and GRAIL, Inc. on 2.
Valuation
Profitability
| Metric | BLLN | GRAL | Diagnostics & Research median |
|---|---|---|---|
| Gross margin | 71.27% | (31.31%) | 50.89% |
| Operating margin | 10.90% | (338.40%) | (8.57%) |
| Net margin | 8.35% | (236.95%) | (6.37%) |
| Free cash flow margin | 8.35% | (179.21%) | 0.00% |
| Return on equity | 23.27% | (16.12%) | (2.92%) |
| Return on assets | 9.09% | (14.12%) | (6.71%) |
| Return on invested capital | 34.10% | (20.79%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack